Allergan, Inc.

Allegro Pharmaceuticals, LLC

S.k. Pharmaceuticals, Inc.

Other

Safran Passenger Innovations, LLC

Smithkline Beecham Corporation

Ista Pharmaceuticals, Inc.

Kato Pharmaceuticals, Inc.

Numoda Biotechnologies, Inc.

Jenius Pharma, LLC

John Y Park

Anthony J Dziabo

Hampar L Karageozian

James N Cook

Michael John Mackel

Vicken H Karageozian

Lin Peng

Samuel Allen Carswell

Daniel P Cafaro

Austin Cotler

Ernesto Ramirez

Steve Sargeant

Claude B Anger

David Castillejos

Anthony B Nesburn

Paul S Ripley

Dorla Mirejovsky

Larry K Thomas

Steven S Matsumoto

Gabriel Arthuro Carpio Aragon

Shurl A Thompson

Jose Luis Gutierres Floress

Dong W Park

Phillip Baker

Hamper Karageozian

Graham Rippel

Eugene Sartini

Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.

Treatments for diseases and disorders that involve oxidative stress

An entertainment system including a removable seat-back display unit and a docking station. The seat-back display unit can include a rotating latch butterfly release mechanism that prevents unauthorized release of the display unit from the docking station. The system can include a three-point attachment system that provides additional protection against accidental detachment of the display unit, and provide safety in the event of partial dislodging. The system can include a current control pin system that ensures that current is not provided from the docking station to the display unit until the respective connectors have been properly engaged. The system can also include a heat dissipation system that employs the docking station to share the heat dissipation load with the display unit.

Display unit for a vehicle

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH&#x2014;CH(CH&#x2014;SOH)COOH or Arg-Gly-NH&#x2014;CH(CH&#x2014;SOH)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to &#x3b1;&#x3b2;-Integrin, &#x3b1;&#x3b2;-Integrin and &#x3b1;&#x3b2;-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Peptide therapies for reduction of macular thickening

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH&#x2014;CH(CH&#x2014;SOH)COOH or Arg-Gly-NH&#x2014;CH(CH&#x2014;SOH)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Pharmaceutical compositions and preparations for administration to the eye

An entertainment system including a removable seat-back display unit and a docking station. The seat-back display unit can include a rotating latch butterfly release mechanism that prevents unauthorized release of the display unit from the docking station. The system can include a three-point attachment system that provides additional protection against accidental detachment of the display unit, and provide safety in the event of partial dislodging. The system can include a current control pin system that ensures that current is not provided from the docking station to the display unit until the respective connectors have been properly engaged. The system can further include a floating pin connector dock that can allow for installation of the display unit even when the connectors of the display unit and docking station become misaligned. The system can also include a heat dissipation system that employs the docking station to share the heat dissipation load with the display unit.

Peptides useable for treatment of disorders of the eye

Peptides useable for treating cancer

Compositions and methods for treating and preventing arthropod infestation are disclosed. A method of treating an arthropod infestation in a subject in need thereof, the method comprising administering topically to the subject an effective amount of either an insecticidal composition consisting essentially of at least one essential oil and a pentacyclosiloxane or an insecticidal composition comprising at least one essential oil, a pentacyclosiloxane, and a mineral oil.

Use of silicone fluids as insecticides

Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites

Integrin receptor antagonists and their methods of use

Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)

Stabalized glycosaminoglycan preparations and related methods

Peptide compositions and therapeutic uses thereof

Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).

Stabilized glycosaminoglycan preparations and related methods

Growing community of inventors

Santa Ana, CA, United States of America

John Y Park